Research in the Alfredo Kirkwood Laboratory is directed toward elucidating the basic mechanisms by which visual experience can modify cortical connections in the visual cortex and how those mechanisms are regulated. In visual cortical slices, we investigate two forms of activity-dependent synaptic plasticity: long-term potentiation (LTP) and long-term depression (LTD). These two forms of synaptic plasticity are currently the most comprehensive models of the elementary mechanisms underlying naturally occurring plasticity. We are currently focused on how synaptic inhibition and the action of neuromodulators regulate the induction of LTP and LTD during development. We hope to gain a better understanding of how naturally occurring plasticity is regulated.

The Aliaksei Pustavoitau Lab conducts research on models and mechanisms of impaired consciousness in patients who have suffered acute brain injury. Examples of our work include a study on the mechanisms of neurologic failure in critical illness and another on the use of intensivist-driven ultrasound at the PICU bedside. We also have a longstanding interest in patient safety and quality of care in the ICU setting.

Research in the Alicia Arbaje Lab aims to help older adults maintain dignity and quality of life as they age. We are particularly interested in creating health care systems to improve safety and outcomes for older adults.

The Aline Charabaty Lab performs clinical research on Inflammatory Bowel Disorder.

Research in the Alison E. Turnbull Lab focuses on patient-clinician interactions. We study decision-making processes for ICU patients and their families and focus on the long-term outcomes of ICU survivors. Additional research examines ways to improve end-of-life care for patients.

Research in the Alison Miles Lab focuses on moral distress among pediatric intensive care unit (PICU) clinicians. We have interviewed practitioners involved in the long-term care of patients in the PICU from two months to two years. By identifying the challenges of these cases and what was learned, we hope to develop more effective stress-management strategies for providers. Providers who have less stress are better equipped to care for patients, including those living with chronic diseases. Our team hopes to ultimately improve the field of pediatric palliative care for patients, families and care providers.

The Alison Moliterno Lab studies the molecular pathogenesis of myeloproliferative disorders (MPDs), including polycythemia vera, essential thrombocytosis and idiopathic myelofibrosis. Our research is focused on the genetic and epigenetic lesions associated with MPDs, with the goal of improving diagnosis and treatment for these disorders.

The Allan Gelber Lab conducts research on the clinical epidemiology of rheumatic disorders. Our recent studies have explored topics that include the predicting factors of prevalent and incident gout; cardiovascular disease burden and risk in patients with rheumatoid arthritis; autoantibodies in both primary and secondary SjogrenÕs syndrome; and predictors of outcomes in patients with scleroderma. In addition, we have a long-standing interest in the ways in which racial differences affect disease manifestations in relation to rheumatic disorders.

Research in the Allan Gottschalk Lab focuses on the mechanisms behind neuropathic pain, chronic pain related to nerve injury. We are investigating biophysical models of the impact of general anesthesia on the central nervous system; informational aspects of sensory perception and the representation of sensory input; nonlinear dynamics of respiratory pattern generation; and acute perioperative pain.

The ALS Center for Cell Therapy and Regeneration Research at Johns Hopkins is committed to identifying the causes of the neurodegenerative disease, amyotrophic lateral sclerosis (ALS), and discovering new and effective treatment options. At the ALS Center, Johns Hopkins researchers work with other investigators, including those at the Robert Packard Center for ALS Research at Johns Hopkins and clinicians within the Johns Hopkins ALS Clinic to aggressively take groundbreaking scientific discoveries and turn them into clinical applications that will improve the quality of life of those diagnosed with ALS.